(2023)
Open-Label, Multicenter, Randomized, Biomarker-Integrated Umbrella Trial for Second-Line Treatment of Advanced Gastric Cancer: K-Umbrella Gastric Cancer Study.
JOURNAL OF CLINICAL ONCOLOGY.
1,
1
(2023)
A Multicenter, Prospective, Observational Study to Evaluate Ethanol-Induced Symptoms in Patients Receiving Docetaxel Chemotherapy.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
Trastuzumab Combined With Ramucirumab and Paclitaxel in Patients With Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Advanced Gastric or Gastroesophageal Junction Cancer.
JOURNAL OF CLINICAL ONCOLOGY.
41,
1
(2023)
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
PLOS ONE.
18,
1
(2023)
Evaluation of Pretreatment Albumin–Bilirubin Grade as a Better Prognostic Factor Compared to Child–Pugh Classification in Patients with Hepatocellular Carcinoma Receiving Transarterial Chemoembolization Combined with Radiotherapy.
JOURNAL OF PERSONALIZED MEDICINE.
13,
2
(2023)
Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study.
BREAST CANCER-TARGETS AND THERAPY.
15,
(2022)
A Pilot Study of Peritumor Administration of 5-FU for Preventing Bleeding in Advanced Gastric Cancer.
The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi.
80,
6
(2022)
Impact of cumulative hyperglycemic burden on the pancreatic cancer risk: A nationwide cohort study.
DIABETES RESEARCH AND CLINICAL PRACTICE.
195,
-
(2022)
A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer.
NATURE COMMUNICATIONS.
13,
1
(2022)
A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10).
CANCER RESEARCH AND TREATMENT.
55,
4
(2022)
Potential anticancer effect of sodium caprate on human gastric cancer cells.
HUMAN & EXPERIMENTAL TOXICOLOGY.
41,
(2022)
Clinical outcomes and prognostic factors of cone-beam CT-guided radiofrequency ablation for pulmonary metastases
in colorectal cancer patients.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY.
(2021)
New prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy.
WORLD JOURNAL OF GASTROENTEROLOGY.
27,
48
(2021)
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE-063): A randomized, open-label, phase 3 trial in Asian patients.
CANCER.
128,
5
(2021)
Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trial.
BMJ OPEN.
11,
12
(2021)
Venous Invasion Perineural Invasion as Upstaging Poor Prognostic Factors in N0 Gastric Cancers.
ANTICANCER RESEARCH.
41,
11
(2021)
Korean clinical practice guideline for pancreatic cancer 2021: A summary of evidence-based, multi-disciplinary diagnostic and therapeutic approaches.
PANCREATOLOGY.
21,
7
(2021)
Trends in Chemotherapy Patterns and Survival of Patients with Advanced Gastric Cancer over a 16-Year Period: Impact of Anti-HER2-Targeted Agent in the Real-World Setting.
CANCER RESEARCH AND TREATMENT.
53,
2
(2021)
Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH.
18,
6
(2021)
Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study.
CANCERS.
13,
2
단행본
(2018)
췌장암 바로알기.
MMK 커뮤니케이션즈.
공동
학술회의논문
(2023)
Exploring the role of progranulin in advanced gastric cancer: A retrospective analysis using K-means cluster.
KINGCAWEEK.
대한민국
(2023)
A phase 1B/2 study of trastuzumab, bevacizumab with paclitaxel for HER2-positive gastric cancer in a second-line therapy (TREAZURE).
2023 International Conference (KSMO 2023).
대한민국
(2023)
Three-year follow-up of the ATTRACTION-4 Korean subgroup analysis: First-line (1L) nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with previously untreated, advanced, or recurrent gastric/gastro-esophageal junction (G/GEJ) cancer.
2023 International Conference (KSMO 2023).
대한민국
(2023)
Comparison of efficacy between immune checkpoint inhibitors and irinotecan-based chemotherapy as third-line treatment for patients with advanced gastric cancer: A Korean real-world multicenter study (KCSG ST22-06)..
2023 ASCO Annual Meeting.
미국
(2022)
Multicenter phase Ib/II study of second-line varlitinib and paclitaxel in patients with EGFR/HER2 co-expressing advanced gastric cancer (K-MASTER-13).
ESMO Congress 2022.
프랑스
(2022)
Predicting tolerability of high-dose fentanyl buccal tablets in cancer patients.
KSMO 2022.
대한민국
(2022)
A Pilot Study of Peritumor Administration of 5-FU for Preventing Bleeding in Advanced Gastric Cancer.
KINGCA Week 2022.
대한민국
(2022)
The first report of K-Umbrella Gastric Cancer Study: An open label, multi-center, randomized, biomarker-integrated trial for second-line treatment of advanced gastric cancer (AGC)..
2022 ASCO Annual Meeting.
미국
(2022)
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: Updated HER-RAM study with biomarker analysis..
ASCO Gastrointestinal Cancers Symposium.
미국
(2021)
Metastatic colorectal cancer patient with tumefactive demyelinating lesion from NMOSD.
대한내과학회 추계학술대회.
대한민국
(2021)
Sunitinib-induced Severe Gastroenteritis including Necrotizing Esophagitis.
대한내과학회 추계학술대회.
대한민국
(2021)
A randomized phase III study to compare efficacy and safety between combination therapy and monotherapy as first-line chemotherapy in elderly patients with advanced gastric cancer (KCSG ST13-10).
ESMO CONGRESS 2021.
EU연합
(2021)
A new prognostic model for patients with advanced gastric cancer: Fluoropyrimidine/platinum doublet for first-line chemotherapy.
14th Annual Meeting of the Korean Society of Medical Oncology.
대한민국
(2021)
Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study)..
2021 ASCO Annual Meeting.
미국
(2021)
Open label, single-arm, multi-center phase Ib/II study to evaluate the safety and efficacy of nivolumab in combination with paclitaxel in Epstein-Barr virus (EBV)-related, or microsatellite instability-high (MSI-H), or programmed cell death ligand 1 (PD-L1) positive advanced gastric cancer (AGC).
American Association for Cancer Research Annual Meeting.
미국
(2021)
A multi-institutional phase Ib/II trial of first-line triplet regimen (Pembrolizumab, Trastuzumab, Chemotherapy) for HER2-positive advanced gastric and gastroesophageal junction cancer (PANTHERA Trial): Molecular profiling and clinical update..
2021 Gastrointestinal Cancers Symposium.
미국
(2020)
Modified prognostic model in patients who received chemotherapy for metastatic or recurrent gastric cancer.
KINGCA Week 2020.
대한민국
(2020)
Do we consider to apply the value framework of cancer drugs to clinical practice and health insurance coverage in Korea?.
ASCO Annual Meeting.
미국
(2020)
Pembrolizumab vs paclitaxel as second-line treatment for Asian patients with PD-L1–positive advanced gastric or gastroesophageal cancer (GC) in the phase III KEYNOTE-063 trial..
ASCO Annual Meeting.
미국
(2020)
Targeting HER2 in combination with anti-PD-1 and chemotherapy confers a significant tumor shrinkage of gastric cancer: A multi-institutional phase Ib/II trial of first-line triplet regimen (pembrolizumab, trastuzumab, chemotherapy) for HER2-positive advanced gastric cancer (AGC)..
ASCO Annual Meeting.
미국
